دورية أكاديمية
Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
| العنوان: | Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. |
|---|---|
| المؤلفون: | Gillet Y; Hôpital Femme Mère Enfant, Urgences Pédiatriques Lyon France, 59 Bd Pinel, 69500 BRON, France. yves.gillet@chu-lyon.fr, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P |
| المصدر: | Vaccine [Vaccine] 2009 Jan 14; Vol. 27 (3), pp. 446-53. Date of Electronic Publication: 2008 Nov 11. |
| نوع المنشور: | Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0264-410X (Print) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Amsterdam, The Netherlands : Elsevier Science Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983- |
| مواضيع طبية MeSH: | Chickenpox Vaccine/*adverse effects , Chickenpox Vaccine/*immunology , Measles-Mumps-Rubella Vaccine/*adverse effects , Measles-Mumps-Rubella Vaccine/*immunology, Antibodies, Viral/blood ; Child ; Child, Preschool ; Female ; Humans ; Immunization, Secondary/adverse effects ; Infant ; Male ; Vaccines, Combined |
| مستخلص: | In this open, randomized, comparative study (105908/NCT00353288), 458 age-stratified children (15 months-2 years and 2-6 years) previously primed with MMR received one dose of either a combined MMRV vaccine (Priorix-Tetra, MMRV group) or concomitant MMR and varicella vaccines (Priorix and Varilrix, MMR+V group), followed 42-56 days later by another dose of varicella vaccine (Varilrix) in both groups. Post-vaccination measles, mumps and rubella seropositivity rates and antibody geometric mean titers (GMTs) were high (99.5% for anti-measles and 100% for anti-mumps and anti-rubella) in both vaccine groups. In the two age strata, varicella seroconversion rates were, post-dose 1: > or =97.6% (MMRV), > or =96.6% (MMR+V) and, post-dose 2: 100% in both groups. Post-dose 2, anti-varicella GMTs increased respectively 14.1- and 12.6-fold (MMRV), and 9.8- and 13.1-fold (MMR+V). Both vaccine regimens were well-tolerated. Post-dose 1, the incidence of any solicited local symptom during the 4-days follow-up was < or =28.2% (MMRV) and < or =19.8% (MMR+V) and the incidence of fever >39.5 degrees C (rectal temperature) within 15 days was < or =2.8% (MMRV) and < or =2.6% (MMR+V). This MMRV vaccine appears an immunogenic and safe substitute for a second dose of MMR vaccine in young children. The increase in anti-varicella antibodies observed after a second dose of varicella vaccine supports a two-dose schedule for varicella-containing vaccine. |
| المشرفين على المادة: | 0 (Antibodies, Viral) 0 (Chickenpox Vaccine) 0 (Measles-Mumps-Rubella Vaccine) 0 (Vaccines, Combined) 0 (measles, mumps, rubella, varicella vaccine) |
| تواريخ الأحداث: | Date Created: 20081115 Date Completed: 20090310 Latest Revision: 20121115 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.vaccine.2008.10.064 |
| PMID: | 19007835 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 0264-410X |
|---|---|
| DOI: | 10.1016/j.vaccine.2008.10.064 |